Leerink Partnrs Has Positive Outlook of RVMD FY2025 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Stock analysts at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Revolution Medicines in a report released on Thursday, May 8th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($4.68) per share for the year, up from their previous forecast of ($4.70). The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines' FY2026 earnings at ($5.40) EPS.

RVMD has been the topic of several other reports. Stifel Nicolaus dropped their target price on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Oppenheimer upped their target price on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday. HC Wainwright increased their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Guggenheim lowered their price objective on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a report on Thursday. Finally, Needham & Company LLC reissued a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a report on Thursday. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Revolution Medicines presently has a consensus rating of "Buy" and an average target price of $67.17.

Revolution Medicines Price Performance

Shares of RVMD stock opened at $40.58 on Monday. Revolution Medicines has a fifty-two week low of $29.17 and a fifty-two week high of $62.40. The stock's 50-day moving average is $37.36 and its two-hundred day moving average is $43.39. The firm has a market cap of $7.56 billion, a P/E ratio of -11.30 and a beta of 1.11.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the prior year, the business earned ($0.70) earnings per share.

Insider Transactions at Revolution Medicines

In other news, COO Margaret A. Horn sold 3,058 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $119,384.32. Following the completion of the transaction, the chief operating officer now directly owns 153,533 shares in the company, valued at $5,993,928.32. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jack Anders sold 1,864 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock worth $650,406 over the last three months. 8.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Barclays PLC raised its stake in shares of Revolution Medicines by 187.1% in the third quarter. Barclays PLC now owns 294,664 shares of the company's stock valued at $13,362,000 after purchasing an additional 192,021 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Revolution Medicines by 92.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 61,980 shares of the company's stock valued at $2,711,000 after purchasing an additional 29,853 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Revolution Medicines by 9.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,931,114 shares of the company's stock valued at $84,467,000 after purchasing an additional 167,997 shares in the last quarter. Sandy Cove Advisors LLC acquired a new position in shares of Revolution Medicines in the fourth quarter valued at $1,837,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Revolution Medicines by 11.4% in the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock valued at $186,000 after purchasing an additional 434 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.